- Home
- SWTX vs ARWR Comparison
SWTX vs ARWR Comparison
Compare SWTX & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWTX
- ARWR
- Stock Information
- Founded
- SWTX 2017
- ARWR 2003
- Country
- SWTX United States
- ARWR United States
- Employees
- SWTX N/A
- ARWR N/A
- Industry
- SWTX Biotechnology: Pharmaceutical Preparations
- ARWR Biotechnology: Pharmaceutical Preparations
- Sector
- SWTX Health Care
- ARWR Health Care
- Exchange
- SWTX Nasdaq
- ARWR Nasdaq
- Market Cap
- SWTX 3.0B
- ARWR 2.5B
- IPO Year
- SWTX 2019
- ARWR 1993
- Fundamental
- Price
- SWTX $47.41
- ARWR $13.82
- Analyst Decision
- SWTX Strong Buy
- ARWR Buy
- Analyst Count
- SWTX 5
- ARWR 11
- Target Price
- SWTX $72.40
- ARWR $41.44
- AVG Volume (30 Days)
- SWTX 2.0M
- ARWR 1.6M
- Earning Date
- SWTX 05-01-2025
- ARWR 05-08-2025
- Dividend Yield
- SWTX N/A
- ARWR N/A
- EPS Growth
- SWTX N/A
- ARWR N/A
- EPS
- SWTX N/A
- ARWR N/A
- Revenue
- SWTX $191,589,000.00
- ARWR $2,500,000.00
- Revenue This Year
- SWTX $85.98
- ARWR $4,380.43
- Revenue Next Year
- SWTX $69.16
- ARWR $59.62
- P/E Ratio
- SWTX N/A
- ARWR N/A
- Revenue Growth
- SWTX 3417.33
- ARWR N/A
- 52 Week Low
- SWTX $28.21
- ARWR $13.66
- 52 Week High
- SWTX $62.00
- ARWR $30.41
- Technical
- Relative Strength Index (RSI)
- SWTX 44.48
- ARWR 31.81
- Support Level
- SWTX $45.88
- ARWR $14.69
- Resistance Level
- SWTX $51.43
- ARWR $15.65
- Average True Range (ATR)
- SWTX 2.12
- ARWR 0.79
- MACD
- SWTX -0.66
- ARWR -0.07
- Stochastic Oscillator
- SWTX 23.47
- ARWR 6.00
About SWTX SpringWorks Therapeutics Inc.
SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.